<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902025000200131</article-id>
<article-id pub-id-type="doi">10.29262/ram.v72i2.1444</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Eosinophilic esophagitis with refractory response in a pediatric patient: A case report]]></article-title>
<article-title xml:lang="es"><![CDATA[Esofagitis eosinofílica en un paciente pediátrico resistente al tratamiento: reporte de un caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Agrela-Mendes]]></surname>
<given-names><![CDATA[Isamar de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tomás-Perez]]></surname>
<given-names><![CDATA[Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario La Paz  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Investigación (IDiPAZ)  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>72</volume>
<numero>2</numero>
<fpage>131</fpage>
<lpage>135</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902025000200131&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902025000200131&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902025000200131&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: The treatment of eosinophilic esophagitis (EoE) is based on diets or drugs, with either being the first choice. Proton pump inhibitor (PPI) or swallowed topical corticosteroids (STC) are classically used, and more recently the use of dupilumab has been described as a therapeutic option.  Case report: A pediatric patient with difficult-to-manage eosinophilic esophagitis, diagnosed before the age of 2 years, in which the simultaneous use of triple pharmacological therapy (Dupilumab, PPI and STC) has been necessary for the histological control of the disease.  Conclusions: It is a case of interest since in current guidelines the use of combined pharmacological therapies is not recommended or fully described. In addition, it is a case in which a good response to treatment with dupilumab is observed despite not meeting the indication criteria of the pharmacological label, in terms of age and weight.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El tratamiento de pacientes con esofagitis eosinofílica consiste en dieta o fármacos, y cualquiera de ambas opciones puede considerarse de primera línea. Los inhibidores de la bomba de protones o los corticosteroides tópicos deglutidos se indican de forma convencional, y recientemente se ha descrito la prescripción de dupilumab como opción terapéutica.  Reporte de caso: Paciente pediátrico, con esofagitis eosinofílica de difícil control, diagnosticada antes de los 2 años, en quien fue necesario la prescripción de un esquema triple de tratamiento (dupilumab, inhibidores de la bomba de protones y corticosteroides tópicos deglutidos) para el control histológico de la enfermedad.  Conclusión: El caso aquí expuesto resulta interesante, puesto que en las guías actuales no se recomienda ni se describe por completo el tratamiento farmacológico combinado. No obstante, dupilumab fue efectivo, aunque no cumple con los criterios de indicación de la ficha farmacológica, en cuanto a edad y peso.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Eosinophilic esophagitis]]></kwd>
<kwd lng="en"><![CDATA[Pediatric patients]]></kwd>
<kwd lng="en"><![CDATA[Proton pump inhibitor]]></kwd>
<kwd lng="en"><![CDATA[Corticosteroids]]></kwd>
<kwd lng="en"><![CDATA[Dupilumab]]></kwd>
<kwd lng="en"><![CDATA[Diet]]></kwd>
<kwd lng="es"><![CDATA[Esofagitis eosinofílica]]></kwd>
<kwd lng="es"><![CDATA[Pacientes pediátricos]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de la bomba de protones]]></kwd>
<kwd lng="es"><![CDATA[Corticosteroides]]></kwd>
<kwd lng="es"><![CDATA[Dupilumab]]></kwd>
<kwd lng="es"><![CDATA[Dieta]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucendo]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Infante]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults]]></article-title>
<source><![CDATA[United European Gastroenterol J]]></source>
<year>2017</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>335-58</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Haboubi]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Attwood]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2022</year>
<volume>71</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1459-87</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Votto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Filippo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caimmi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Practical Update on Pediatric Eosinophilic Esophagitis]]></article-title>
<source><![CDATA[Children (Basel)]]></source>
<year>2023</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1620</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González-Cervera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tenlas]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Lucendo]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2014</year>
<volume>146</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1639-48</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Rank]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2020</year>
<volume>158</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1776-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2020</year>
<volume>158</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>840-51</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Horani]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Chiles]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First Therapeutic Approval for Eosinophilic Esophagitis]]></article-title>
<source><![CDATA[Gastroenterol Insights]]></source>
<year>2022</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>238-44</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dellon]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Rothenberg]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupllumab in Adults and Adolescents with Eosinophilic Esophagitis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>387</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2317-30</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
